US Stock MarketDetailed Quotes
ATRA Atara Biotherapeutics
- 7.010
- +0.180+2.64%
Close Aug 16 16:00 ET
- 7.010
- 0.0000.00%
Post 19:39 ET
34.45MMarket Cap-179P/E (TTM)
7.130High6.500Low125.49KVolume7.010Open6.830Pre Close843.44KTurnover3.73%Turnover RatioLossP/E (Static)4.92MShares49.00052wk High-0.31P/B23.61MFloat Cap4.96552wk Low--Dividend TTM3.37MShs Float1638.998Historical High--Div YieldTTM9.22%Amplitude4.965Historical Low6.721Avg Price1Lot Size
Atara Biotherapeutics Stock Forum
Sign in to post a comment
$Atara Biotherapeutics (ATRA.US)$
Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
Atara Biotherapeutics (Nasdaq: ATRA) reported Q2 2024 financial results and operational progress. Key highlights include:
1. Tab-cel® U.S. BLA accepted under Priority Review with PDUFA date of January 15, 2025.
2. ATA3219 studies in Lupus Nephritis and Severe Systemic Lupus Erythematosus to start Q4 2024; initial data expected mid-2025.
3. ATA3...
Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
Atara Biotherapeutics (Nasdaq: ATRA) reported Q2 2024 financial results and operational progress. Key highlights include:
1. Tab-cel® U.S. BLA accepted under Priority Review with PDUFA date of January 15, 2025.
2. ATA3219 studies in Lupus Nephritis and Severe Systemic Lupus Erythematosus to start Q4 2024; initial data expected mid-2025.
3. ATA3...
1
5
$Atara Biotherapeutics (ATRA.US)$ Reuters· PDUFA for BLA is January 20th
Atara Biotherapeutics- Bla Acceptance Triggers $20 Mln Milestone Payment With Additional $60 Mln Milestone if Approved by FDA
Atara Biotherapeutics- Bla Acceptance Triggers $20 Mln Milestone Payment With Additional $60 Mln Milestone if Approved by FDA
$Atara Biotherapeutics (ATRA.US)$ Atara Biotherapeutics To Conduct 1-for-25 Reverse Stock Split, Effective Jun. 20
1
4
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Atara Biotherapeutics (ATRA.US)$ Reuters· 7 mins ago
Atara Biotherapeutics - Preclinical Results Support Advancing ATA3219 Towards Clinical Evaluation in Patients With B-Cell Driven Autoimmune Diseases
Atara Biotherapeutics - Preclinical Results Support Advancing ATA3219 Towards Clinical Evaluation in Patients With B-Cell Driven Autoimmune Diseases
3
$Atara Biotherapeutics (ATRA.US)$
Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
Atara Biotherapeutics has announced promising preclinical data for ATA3219, an allogeneic CD19-targeted CAR T therapy aimed at treating B-cell driven autoimmune diseases such as systemic lupus erythematosus (SLE) and multiple sclerosis (MS). The data, to be presented at th...
Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
Atara Biotherapeutics has announced promising preclinical data for ATA3219, an allogeneic CD19-targeted CAR T therapy aimed at treating B-cell driven autoimmune diseases such as systemic lupus erythematosus (SLE) and multiple sclerosis (MS). The data, to be presented at th...
1
$Atara Biotherapeutics (ATRA.US)$
NEWS
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
05/20/2024 - 06:25 AM First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration If Approved, Tab-cel Would be First Approved Therapy in U.S. for EBV+ PTLD Acceptance of BLA Will Trigger $20 Million Milestone Payment from Pierre Fabre Laboratories, ...
NEWS
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
05/20/2024 - 06:25 AM First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration If Approved, Tab-cel Would be First Approved Therapy in U.S. for EBV+ PTLD Acceptance of BLA Will Trigger $20 Million Milestone Payment from Pierre Fabre Laboratories, ...
1
$Atara Biotherapeutics (ATRA.US)$ looks like in buy range
$Atara Biotherapeutics (ATRA.US)$ PAY VERY CLOSE ATTENTION TO THE LAST 3 BULLET POINTS! This could be a catalyst for a large price increase? Even if its only a temporary increase? I want you to have ample opportunity to catch ahead of time if YOU CHOOSE? Not me choosing for YOU! NFA! Just a heads up for the possibility! Tab-cel U.S. BLA on Track for Submission in Q2 2024 Following Positive Pre-BLA Me...
10
15
$Atara Biotherapeutics (ATRA.US)$ Tab-cel U.S. BLA on Track for Submission in Q2 2024 Following Positive Pre-BLA Meeting
Allogeneic CAR T Pipeline Expands Into Autoimmune Disease With Plans To Initiate a ATA3219 Lupus Nephritis Study in H2 2024, and Initial Clinical Data Expected H1 2025
ATA3219 NHL Study Enrolling With Initial Clinical Data Expected in Q4 2024
Cash Runway Into 2027 Enables Key Pipeline Readouts
Allogeneic CAR T Pipeline Expands Into Autoimmune Disease With Plans To Initiate a ATA3219 Lupus Nephritis Study in H2 2024, and Initial Clinical Data Expected H1 2025
ATA3219 NHL Study Enrolling With Initial Clinical Data Expected in Q4 2024
Cash Runway Into 2027 Enables Key Pipeline Readouts
4
1
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
Trytosaveabit : I can’t believe with the monster revenue increase this isn’t moving! Over 2000% increase
Jaguar8 OP Trytosaveabit : Maybe let’s wait tomorrow. Maybe they are too happy with their GNLN earnings![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Trytosaveabit Jaguar8 OP : Hehehe! Yeah you’re right.
Joo Mey : hye dude..what do you think about ffie?
Jaguar8 OP Joo Mey : I try to avoid it. Super high ritual for dilution. Negative cash flow